alexa HIV to AIDS–The Dynamics of HIV–1 Infection | OMICS International
ISSN: 2161-0703
Journal of Medical Microbiology & Diagnosis

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

HIV to AIDS–The Dynamics of HIV–1 Infection

Nageswara R Alla1*, Harika S Polamarasetty2 and Zhongjie Shi3

1 Department of Pulmonary and Critical Care Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA -15213, USA

2 Department of Biochemistry, Gitam University, Visakhapatnam, Andhra Pradesh, India

3 Department of Cancer Biology, Thomas Jefferson University, USA

*Corresponding Author:
Nageswara R Alla
Department of Pulmonary and Critical Care Medicine
School of Medicine, University of Pittsburgh
Pittsburgh, PA -15213,USA
Tel: 1-215-301-1427
E-mail: [email protected]

Received Date: January 21, 2014; Accepted Date: January 22, 2014; Published Date: January 24, 2014

Citation: Alla NR, Polamarasetty HS, Shi Z (2014) HIV to AIDS – The Dynamics of HIV–1 Infection. J Med Microb Diagn 3:e123. doi: 10.4172/2161-0703.1000e123

Copyright: © 2014 Alla NR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Medical Microbiology & Diagnosis

In the course of 30 years since the discovery of HIV as the causative agent of AIDS we have made remarkable progress in understanding the biology and pathogenesis of the virus and the field of viral dynamics has been critical for understanding the details of progression of HIV infection to AIDS. A typical primary infection is characterized by high levels of viral titers in plasma [1,2] with concomitant decrease in the CD4+ T cell numbers. At the end of primary infection stage the viral titers decline due to depletion of CD4+ T cells and partial immune activation [3,4]. Few months later the virus enters the chronic stage typified by a slow increase in the viral titers and gradual decrease in the CD4+ T cell levels [3,4], immune activation, increased cell turnover and destruction of host immune system [5]. The final stage leading to AIDS and consequently to death is characterized by rising viral titers and decrease of CD4+ T cells to a level where immune control over viral infection is lost [3,4].

Studying dynamics of HIV infection under suppressive Antiretroviral Therapy (ART) has offered substantial insights into the pathogenesis of HIV-1. Study by Mellors et al. [6] has revealed the importance of viremia where they showed that patients with higher viral load progressed to AIDS multiple folds faster than the patients with lower viral loads. Studies of decay of virus and productively infected cells (virus producing cells) under suppressive ART regiment using clinical assays with a detection limit of 50 HIV RNA copies/ml have shown that there are two phases of virus and productively infected cell decay [7-9]. A rapid first phase followed by a slow second phase which is accredited to long lived CD4+ T cells or macrophages leading to a quasi-steady state level called set-point [10], where viral titer level and number of virus producing cells remains constant. This concept was called the steady state model. Based on the first phase and second phase decay half-lives it was indicated that prolonged ART could lead to the elimination of virus [11]. However development of single copy assays using real time RT-PCR capable of detecting as low as one HIV mRNA/ml [12] revealed two more phases of viral decay, a third phase with half-life ranging from 39 weeks to 69 weeks [13,14] and a controversial fourth phase with infinite half-life.

Due to subsistence of infected cells capable of making virus after several years (latency) elimination of HIV by ART was ruled out. Hence, it is clear that development of vaccine for prevention of infection is of utmost significance [15]. HIV establishes latency by integrating into the genome of a small fraction of resting CD4+ T cells [16-19]. These latently infected cells cannot produce virus in the resting memory state but they can produce virus on activation [16]. The latent reservoir is maintained by homeostatic proliferation of these latently infected resting CD4+ T cells. It is known that individuals on ART also have latently infected cells, this was demonstrated when HIV infected people on highly active antiretroviral therapy (HAART) regimen for more than year have seen resurgence of virus within two weeks of HAART interruption [20]. Activation of these latently infected reservoirs may occur via immune activation by some co-infection or vaccination. A new therapeutic strategy to lure out the virus from latently infected cells to successfully eliminate it using HAART is an area of extensive research and debate.

Although we acquired a lot of knowledge about HIV over the years, the exact mechanism of disease progression from primary infection to AIDS is still not known. Simple answer is that HIV infects CD4+ T cells and kills and loss of these cells leads to AIDS. In reality it is more complicated than that, because CD4+ T cell death in vivo is contentious. There are two possible mechanisms to kill productively infected cells 1. Viral cytopathicity 2. CD8+ T cell/CTL responses. Another feature of the pathogenic infection is chronic immune activation and high levels of CD4+ T cell killing which subsequently leads to immune exhaustion and damage of lymphoid tissue. Overall it is yet to be determined if the above mentioned mechanisms all together could lead to disease progression. As of now early HAART treatment for primary infection and immunotherapy plus HAART treatment for chronic infection seem to be the best interventions.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 4th Annual Congress on Infectious Diseases  
    September 17-18, 2018 San Diego, USA
  • 13th World Congress on Virology
    September 26-27, 2018 Montreal, Canada

Article Usage

  • Total views: 11815
  • [From(publication date):
    March-2014 - Jul 21, 2018]
  • Breakdown by view type
  • HTML page views : 8032
  • PDF downloads : 3783

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7